Teprenone

Drug Profile

Teprenone

Alternative Names: E 0671; Selbex; Tetraprenylacetone

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Tokyo Womens Medical College
  • Developer EA Pharma
  • Class Antiulcers; Cytoprotectives; Diterpenes
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastritis; Peptic ulcer
  • No development reported Cancer

Most Recent Events

  • 27 Oct 1998 Launched for Gastritis in Japan (PO)
  • 17 Aug 1998 No-Development-Reported for Cancer in Germany (Unknown route)
  • 12 Dec 1996 Launched for Peptic ulcer in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top